Abstract
Background: Ibutilide is currently indicated for the rapid conversion of atrial fibrillation (Afb) or atrial flutter (Afl) of recent onset but limited to patients who are hemodynamically stable and without symptomatic cardiovascular conditions.
Hypothesis: The study was undertaken to assess the efficacy and safety of ibutilide in patients with Afb or Afl associated with acute cardiovascular‐medical disorders and in patients receiving prior selective antiarrhythmic drug therapy.
Methods: The study included 34 patients, mean age 75 ± 16.3 years, with Afb (n = 25) or Afl (n = 9) having a variety of disorders, for example, congestive heart failure, unstable angina, borderline hypotension, respiratory failure, and chronic renal failure. Prior antiarrhythmic drugs consisted of propafenone (n = 5) or amiodarone (n = 3). Eligibility for cardioversion was established with appropriate anticoagulation or transesophageal echocardiography findings. Ibutilide was given as up to two 10 min infusions of 1 mg separated by 10 min.
Results: The overall conversion rate after ibutilide was 79.4% (27/34 patients): 80% for Afb and 78% for Afl. More than 90% converted within 1 h of treatment. A high conversion rate of 92% resulted in those with an arrhythmia duration of ≤ 1 week. All eight patients with prior antiarrhythmic therapy converted to sinus rhythm. The average baseline QTc interval for all patients increased 17.1% (397 ± 63.3 to 465 ± 60.2 ms) at 30 min. For eight patients (including four who received prior antiarrhythmic drugs), QTc interval prolongation ≥ 500 ms was associated with nearly half the entire incidence of arrhythmic events. Proarrhythmia, the exclusive adverse effect, consisted of ventricular extrasystoles (n = 10) and nonsustained monomorphic ventricular tachycardia (VT) (n = 2) managed with intravenous MgSO4, and sustained polymorphic VT (n = 1) requiring electrical cardioversion.
Conclusion: Ibutilide is an effective and well tolerated drug for the rapid termination of Afb or Afl of recent onset associated with symptomatic and/or hemodynamically unstable disorders, and it is most efficacious (≥ 90%) when the atrial arrhythmia is ≤ 1 week in duration. Proarrhythmic events are readily manageable in a monitored unit with access to appropriate treatment.
Keywords: atrial fibrillation, ibutilide, cardioversion, antiarrhythmic drugs
Full Text
The Full Text of this article is available as a PDF (446.9 KB).
References
- 1. Prystowsky EN, Benson DW, Fuster V, Hart RG, Kay GN, Myerburg RJ, Naccarelli GV, Wyse DG: Management of patients with atrial fibrillation: A statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology, American Heart Association. Circulation 1996; 93: 1262–1277 [DOI] [PubMed] [Google Scholar]
- 2. Bialy D, Lehmann MH, Schumacher DN: Hospitalization for arrhythmias in the United States: Importance of atrial fibrillation (abstr). J Am Coll Cardiol 1992; 19: 41A [Google Scholar]
- 3. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawic MA, Stevenson LW: Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998; 32: 695–703 [DOI] [PubMed] [Google Scholar]
- 4. Ellenbogen KA, Stambler BS, Wood MA, Sager PT, Wesley RC, Meissner MD, Zoble RG, Wakefield LK, Perry KT, VanderLugt JT: Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation: A dose–response study. J Am Coll Cardiol 1996; 28: 130–136 [DOI] [PubMed] [Google Scholar]
- 5. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT: Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996; 94: 1613–1621 [DOI] [PubMed] [Google Scholar]
- 6. Cimini MG, Brunden MN, Gibson JK: Effects of ibutilide fumarate, a novel antiarrhythmic agent, and its enantiomers on isolated rabbit myocardium. Eur J Pharmocol 1992; 222: 93–98 [DOI] [PubMed] [Google Scholar]
- 7. Lee KS: Ibutilide, a new compound with potent class III antiarrhythmic activity, activates a slow inward Na current in guinea pig ventricular cells. J Pharmacol Exp Ther 1992; 262: 99–108 [PubMed] [Google Scholar]
- 8. Buchanan LV, Turcotte UM, Kabell GG, Gibson JK: Antiarrhythmic and electrophysiologic effects of ibutilide in a chronic canine model of atrial flutter. J Cardiovasc Pharmacol 1933; 33: 10–14 [DOI] [PubMed] [Google Scholar]
- 9. Nabih MA, Prcevski P, Fromm BS: Effect of ibutilide, a new class III agent, on sustained atrial fibrillation in a canine model of acute ischemia and myocardial dysfunction induced by microembolization. PACE 1993; 16: 1975–1983 [DOI] [PubMed] [Google Scholar]
- 10. Yang T, Snyder DJ, Roden DM: Ibutilide, a methanesulfonamilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K + current (Ikr) in AT‐1 cells: Concentration, time‐, voltage‐ and use‐dependent effects. Circulation 1995; 91: 1799–1806 [DOI] [PubMed] [Google Scholar]
- 11. Volgman AS, Carberry PA, Stambler B, Lewis WR, Dunn GH, Perry KT, VanderLugt JT, Kowey PR: Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 1998; 31: 1414–1419 [DOI] [PubMed] [Google Scholar]
- 12. Sotalol comparator study (protocol 0019) : CorvertTM injection (ibutilide fumarate)—comprehensive review. Appendix I. Kalamazoo, Mich.: Pharmacia & Upjohn, Feb. 1996. [Google Scholar]
- 13. Funck‐Brentano C, Kroemer HK, Lee JT, Roden DM: Propafenone. N Engl J Med 1990; 322: 518–525 [DOI] [PubMed] [Google Scholar]
- 14. Bryson HM, Palmer KJ, Langtry HD: Propafenone: A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias. Drugs 1993; 45 (1): 85–130 [DOI] [PubMed] [Google Scholar]
- 15. Hii JT, Wyse BG, Gillis AM: Precordial QT interval dispersion as a marker of torsade de pointes: Disparate effects of class IA antiarrhythmic drugs and amiodarone. Circulation 1992; 86: 1376–1382 [DOI] [PubMed] [Google Scholar]
- 16. Cui G, Sen L, Sager P: Effects of amiodarone, sematilide and sotalol on QT dispersion. Am J Cardiol 1994; 74: 896–900 [DOI] [PubMed] [Google Scholar]
- 17. Drouin E, Lande G, Charpentier F: Nantes, France: Amiodarone reduces transmural heterogeneity of repolarization in the human heart. J Am Coll Cardiol 1998; 32: 1063–1067 [DOI] [PubMed] [Google Scholar]
- 18. Stambler BS, Beckman KS, Kadish AH, Camm JA, Ellenbogen KA, Perry KT, VanderLugt JT: Acute hemodynamic effects of intravenous ibutilide in patients with or without reduced left ventricular function. Am J Cardiol 1997; 80: 458–463 [DOI] [PubMed] [Google Scholar]
- 19. Murray KT: Ibutilide. Circulation 1998; 97: 493–497 [DOI] [PubMed] [Google Scholar]